Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 126269231 | 12626923 | 1 | I | 20160728 | 20160805 | 20160805 | EXP | US-MYLANLABS-2016M1032118 | MYLAN | DOROUDGAR S, PERRY PJ, LACKEY GD, VESELOVA NG, CHUANG HM, ALBERTSON TE. AN 11-YEAR RETROSPECTIVE REVIEW OF VENLAFAXINE INGESTION IN CHILDREN FROM THE CALIFORNIA POISON CONTROL SYSTEM. HUM-EXP-TOXICOL 2016;35(7):767-774. | 0.00 | Y | 0.00000 | 20160805 | OT | US | US |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 126269231 | 12626923 | 1 | PS | VENLAFAXINE | VENLAFAXINE HYDROCHLORIDE | 1 | Oral | 2250MG (43.3 MG/KG) | U | U | 77166 |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 126269231 | 12626923 | 1 | Mental disorder |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 126269231 | 12626923 | OT |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 126269231 | 12626923 | Abdominal pain | |
| 126269231 | 12626923 | Off label use | |
| 126269231 | 12626923 | Seizure |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| no results found |